Comparative Analysis of In Vitro Models to Study Antibody-Dependent Enhancement of Zika Virus Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
13 12 2022
Historique:
received: 10 11 2022
revised: 02 12 2022
accepted: 08 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

During the 2015-2016 outbreak of Zika virus (ZIKV) in the Americas, a previously unknown severe complication of ZIKV infection during pregnancy resulting in birth defects was reported. Since the ZIKV outbreak occurred in regions that were highly endemic for the related dengue virus (DENV), it was speculated that antibody-dependent enhancement (ADE) of a ZIKV infection, caused by the presence of cross-reactive DENV antibodies, could contribute to ZIKV disease severity. Emerging evidence indicates that, while in vitro models can show ADE of ZIKV infection, ADE does not seem to contribute to congenital ZIKV disease severity in humans. However, the role of ADE of ZIKV infection during pregnancy and in vertical ZIKV transmission is not well studied. In this study, we hypothesized that pregnancy may affect the ability of myeloid cells to become infected with ZIKV, potentially through ADE. We first systematically assessed which cell lines and primary cells can be used to study ZIKV ADE in vitro, and we compared the difference in outcomes of (ADE) infection experiments between these cells. Subsequently, we tested the hypothesis that pregnancy may affect the ability of myeloid cells to become infected through ADE, by performing ZIKV ADE assays with primary cells isolated from blood of pregnant women from different trimesters and from age-matched non-pregnant women. We found that ADE of ZIKV infection can be induced in myeloid cell lines U937, THP-1, and K562 as well as in monocyte-derived macrophages from healthy donors. There was no difference in permissiveness for ZIKV infection or ADE potential of ZIKV infection in primary cells of pregnant women compared to non-pregnant women. In conclusion, no increased permissiveness for ZIKV infection and ADE of ZIKV infection was found using in vitro models of primary myeloid cells from pregnant women compared to age-matched non-pregnant women.

Identifiants

pubmed: 36560779
pii: v14122776
doi: 10.3390/v14122776
pmc: PMC9781448
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Front Immunol. 2017 Dec 06;8:1707
pubmed: 29270173
Cell Immunol. 1988 Jul;114(2):272-81
pubmed: 2968843
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7852-7
pubmed: 27354515
J Virol. 2008 Apr;82(8):3939-51
pubmed: 18272578
J Infect Dis. 2010 Mar 15;201(6):923-35
pubmed: 20158392
Traffic. 2013 Jan;14(1):25-35
pubmed: 22998156
Intervirology. 2020;63(1-6):57-65
pubmed: 33202415
Neurol Neurochir Pol. 1976 Mar-Apr;10(2):231-6
pubmed: 1264339
N Engl J Med. 2016 Mar 10;374(10):951-8
pubmed: 26862926
Lancet Infect Dis. 2010 Oct;10(10):712-22
pubmed: 20883967
Clin Infect Dis. 2017 Oct 15;65(8):1260-1265
pubmed: 29017246
J Infect Dis. 2017 Sep 1;216(5):612-614
pubmed: 28931226
Lancet. 2016 Apr 2;387(10026):1482
pubmed: 27115821
Sci Adv. 2019 Feb 27;5(2):eaav3208
pubmed: 30820456
PLoS Negl Trop Dis. 2022 Apr 20;16(4):e0010359
pubmed: 35442976
J Immunol. 1990 Apr 15;144(8):3183-6
pubmed: 2139079
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28087938
Aust J Exp Biol Med Sci. 1964 Aug;42:465-82
pubmed: 14202187
Cell Host Microbe. 2018 Nov 14;24(5):731-742.e6
pubmed: 30439342
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Emerg Microbes Infect. 2021 Dec;10(1):1024-1037
pubmed: 33979266
J Gene Med. 2021 Feb;23(2):e3297
pubmed: 33217097
Front Immunol. 2017 Aug 02;8:877
pubmed: 28824618
Science. 2010 May 7;328(5979):745-8
pubmed: 20448183
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
PLoS Pathog. 2019 Apr 18;15(4):e1007640
pubmed: 30998804
J Virol. 2015 Sep;89(17):8880-96
pubmed: 26085147
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Nat Immunol. 2016 Sep;17(9):1102-8
pubmed: 27339099
Front Cell Infect Microbiol. 2020 Oct 02;10:580096
pubmed: 33123500
Immunobiology. 2001 Dec;204(4):494-507
pubmed: 11776403
PLoS One. 2018 Jul 25;13(7):e0200478
pubmed: 30044839
Clin Transl Immunology. 2016 Dec 16;5(12):e117
pubmed: 28090318
Cell Host Microbe. 2020 Jan 8;27(1):14-24
pubmed: 31917957
Nat Rev Dis Primers. 2016 Aug 18;2:16055
pubmed: 27534439
J Reprod Immunol. 1998 Nov;40(2):119-28
pubmed: 9881740
Mem Inst Oswaldo Cruz. 2019;114:e190150
pubmed: 31432892
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9172-E9181
pubmed: 30206152
Clin Microbiol Rev. 2009 Oct;22(4):564-81
pubmed: 19822889
Vaccine. 2017 Nov 7;35(47):6355-6358
pubmed: 29029938
J Virol. 1999 Apr;73(4):2650-7
pubmed: 10074110
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
J Infect Dis. 2019 Jan 7;219(2):223-233
pubmed: 30085051
Nat Microbiol. 2017 Nov;2(11):1558-1570
pubmed: 28827581
J Periodontol. 1993 May;64(5 Suppl):456-60
pubmed: 8315568
Nat Rev Immunol. 2020 Oct;20(10):633-643
pubmed: 32782358
Nat Rev Immunol. 2011 Jul 15;11(8):532-43
pubmed: 21760609
N Engl J Med. 2016 May 19;374(20):1981-7
pubmed: 27074377
Front Immunol. 2020 Jul 03;11:1393
pubmed: 32719679
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
PLoS Negl Trop Dis. 2021 Jul 30;15(7):e0009641
pubmed: 34329306
J Inflamm Res. 2016 Nov 16;9:209-219
pubmed: 27895507
PLoS Curr. 2016 Jul 05;8:
pubmed: 27660733
J Infect Dis. 2017 Mar 1;215(5):781-785
pubmed: 28039355
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
Viruses. 2021 Jul 12;13(7):
pubmed: 34372551
Yale J Biol Med. 1970 Apr;42(5):311-28
pubmed: 5419206
Nat Microbiol. 2017 Nov;2(11):1462-1470
pubmed: 28970482
Immunity. 2019 Mar 19;50(3):751-762.e5
pubmed: 30737148
J Gen Virol. 2017 Jul;98(7):1702-1712
pubmed: 28691657
Sci Rep. 2017 Nov 22;7(1):16050
pubmed: 29167459
Science. 2020 Aug 28;369(6507):1123-1128
pubmed: 32855339
Front Neurol. 2021 Feb 10;12:635753
pubmed: 33643209
J Virol. 1988 Nov;62(11):3928-33
pubmed: 2459406

Auteurs

Thomas Langerak (T)

Department of Viroscience, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.

Noreen Mumtaz (N)

Department of Viroscience, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.

Marion Koopmans (M)

Department of Viroscience, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.

Sam Schoenmakers (S)

Division of Obstetrics and Prenatal Diagnosis, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.

Barry Rockx (B)

Department of Viroscience, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH